Pure Global
NCT05543343

Staphylococcus and Neisseria Tablets in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease.

Evaluating the Efficacy and Safety of Staphylococcus and Neisseria Tablets in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
Qu Yiqing·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Pulmonary Disease, Chronic Obstructive
Drug/Device/Intervention
High dose or normal dose staphylococcus albicans
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Qu Yiqing
Funder
Qilu Hospital of Shandong University
Location
Jinan, China
Timeline & enrollment
Phase
N/A
Start date
Jan 05, 2022
End date
Aug 01, 2023
Enrollment
495 participants
Primary outcome

Number of acute exacerbations of chronic obstructive pulmonary disease in 1 year

Summary

It is planned to enroll 495 acute exacerbation of chronic obstructive pulmonary disease
 patients, and they will be randomly assigned to the high-dose test group, normal dose test
 group or control group at a ratio of 1:1:1, with 165 patients in each group. The course of
 treatment is 90 days, and the total follow-up time is one year. The purpose of the study is
 to evaluate the effectiveness and safety of different doses of bacterial lysates
 (Staphylococcus and Neisseria Tablets) in the treatment of acute exacerbation of chronic
 obstructive pulmonary disease.

ICD-10 classifications
Chronic obstructive pulmonary disease, unspecifiedOther chronic obstructive pulmonary diseaseOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05543343
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05543343 through Pure Global AI's free database. This phase not specified trial is sponsored by Qu Yiqing and is currently Recruiting. The study focuses on Pulmonary Disease, Chronic Obstructive. Target enrollment is 495 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.